Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameNT Pharma
Stock Code01011
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國最大的全面綜合疫苗供應鏈及推廣和銷售服務供應商,亦是國內第二大的第三方藥品推廣和銷售服務供應商。業務包括供應鏈服務(清關、倉儲、交付、開具發票、收繳應收款項等)及推廣和銷售服務(向醫療從業人員介紹臨床用途、組織研討會等)。
Listing Date2011-04-20
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港干諾道中168-200號信德中心西座21樓2102室
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitentpharma.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 4.54 / shares
Offer Price RangeTo be extracted
Lot Size500 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2011-04-08 to 2011-04-13
Global Offering Shares357,032,000 shares
HK Public Offer Shares (Initial)35,703,500 shares (10.0%)
Public Offer Lots (Initial)71,407lots (Pool A35,703lots,Pool B35,704lots)
International Placing Shares (Initial)321,328,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,081,916,500 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,620,925,280

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 855.7M
Est. Threshold HK$ 9.37B
Analysis Result HK market cap below threshold, need +995%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣129.4百萬元
Period-End Cash Balance人民幣154.9百萬元
Listing Expenses~HK$ 187,100,000
Listing Expenses / Funds Raised~11.54%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 200820092010
Revenue 1,413,9852,395,0382,667,978
Cost of sales -1,178,904-1,915,167-2,004,775
Gross profit 235,081479,871663,203
Other income and gains, net 48,1967,67028,698
Selling and distribution expenses -108,129-237,418-354,456
Administrative expenses -43,147-55,999-90,056
Operating profit 87,690192,385255,537
Net finance costs -14,277-17,128-45,379
Profit before tax 73,413175,257210,158
Income tax expense -20,150-58,087-80,748
Profit for the year 53,263117,170129,410
Profit attributable to owners 53,263117,170128,610
Balance Sheet
Item 200820092010
Cash and cash equivalents 67,803212,240154,913
Trade and bills receivables 575,5141,213,7541,738,213
Inventories 125,690231,016527,054
Total current assets 820,2691,713,0002,467,260
Total assets 979,0661,947,1882,755,336
Total current liabilities 762,5081,608,3072,250,398
Total liabilities 763,3901,610,3122,253,059
Total equity 215,676336,876502,277
Equity attributable to owners 200,546321,746487,147
Interest-bearing borrowings 186,497510,719840,187
Cash Flow Statement
Item 200820092010
Net cash from operating activities -37,699-251,274-383,235
Net cash from investing activities -66,845-63,019-57,599
Net cash from financing activities 108,201459,611378,104
Net increase in cash 3,657145,318-62,730
Depreciation of PP&E 6,0964,86412,671
Depreciation of right-of-use assets 324324360
Amortisation of intangible assets 4,5954,1174,393
Purchase of PP&E -72,055-63,619-51,167
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 3.82
First Day OpenHK$ 4.2
First Day Change-15.86%
First Day Volume130166000.0
First Day Turnover525403000.0
Use of Proceeds
1、約25%或267.6百萬港元,將主要用于透過自然發 展及合并與收購的方式擴展及提升我們的分銷網絡(以疫苗業務為主)。 ; 2、約25%或267.6百萬港元,將用于提升及擴展我們的基礎設施; 3、約10%或107.1百萬港元,將用作擴充我們的疫苗及藥品推廣團隊; 4、約20%或214.0百萬港元,將用作透過取得其他疫苗及藥品分銷及/或推廣權特許權擴展我們產品的投資組合; 5、約20%或214.0百萬港元,將用于向知名的海外供應商采購進口疫苗或藥品。

Underwriting Syndicate

Sole Sponsor (1)
UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (2)
UBS Securities Hong Kong Limited CE BIN466 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Joint Lead Managers (2)
UBS Securities Hong Kong Limited CE BIN466 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman吳鐵—
Company Secretary吳育強—
No director data available.

Major Shareholders

Major Shareholders & Holdings緊隨全球發售後(假設超額配股權未獲行使),Golden Base持有46.68%,TPG Star持有13.55%,TPG Biotech持有6.77%;吳鐵先生及錢余女士各自持有Golden Base 50%權益,被視為控股股東。
About this page

This page shows NT Pharma (01011) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect